FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Administration Weighs White House Aide for FDA Top Post

[ Price : $8.95]

The Trump Administration considers White House health policy adviser Heidi Overton as a leading candidate to become the next FDA c...

JAMA Publishes Previously Blocked Covid-19 Vaccine Study

[ Price : $8.95]

JAMA publishes a controversial Covid-19 vaccine effectiveness study, which was previously blocked from publication in a Centers fo...

FDA FY 2027 Appropriation Report Analyzed

[ Price : $8.95]

Eight Hyman, Phelps & McNamara attorneys analyze a House Appropriations Committee report that explains its rationale and expectati...

FTC Weighs in Against J&J in Stelara Monopoly Case

[ Price : $8.95]

The Federal Trade Commission files an amicus brief supporting plaintiffs in an antitrust lawsuit accusing Johnson & Johnson of unl...

FDA Details Standardized Approach to Drug Safety Signal Detection

[ Price : $8.95]

A new CDER Office of New Drugs webinar discusses the development and use of OND Custom Medical Queries to identify potential safet...

Require IDE for Venas MicroAngioscope: Petition

[ Price : $8.95]

Harmed Americans for Reform in Medical Device Safety petitions FDA to require an IDE for the Vena MicroAngioscope and take other s...

FDA Making Good Progress Hiring New Staff: Zeta

[ Price : $8.95]

Speaking at a BIO International Convention FDA Town Hall, several agency executives cite increases in hiring and decreases in attr...

JAMA Revisits FDA's Controversial OK of Depression Drug Gepirone

[ Price : $8.95]

A new analysis published in JAMA Psychiatry raises fresh questions about how FDA evaluates drug efficacy when clinical trial resul...

FDA Expands Ibrance for Breast Cancer Maintenance

[ Price : $8.95]

FDA grants Pfizer expanded approval for Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy...

Drug Trial Demographic Info Reported

[ Price : $8.95]

FDA publishes a report summarizing demographic information from pivotal trials supporting 46 novel new drugs approved in 2025.